FTP3.10 Does Anti-Thrombotic Medication affect the PPV of the Feacal Immunochemical Test: A Single Centre Retrospective Study

Abstract Aims Our aim of this study was to determine whether anti-thrombotic medication (i.e. anit-coagulative's such as DOACS and anti-platelets) had a causal relationship to the outcome of the FIT score by looking at the PPV in its detection for malignancy and significant neoplasm. Methods We analysed records of 500 patients over 2 years (June 2020 - June 2022) from a single centre database of patients who are FIT positive and we reviewed all their endoscopy and CT images to determine the proportion of patients with a diagnosis of Colorectal Malignancy and advanced colorectal neoplasm. Results The key finding from our data we discovered that the PPV of having a Colorectal Malignancy/Advanced Neoplasm was significantly lower for patients who were on anti-thrombotic medication (33.1%) when compared to patients who were not on any anti-thrombotic medication (48.8%). Conclusion Our findings display that the use of anti-thrombotic medication lowered the incidence of significant colorectal neoplasms and malignancies detected on colonoscopy or CT imaging for patients who are FIT positive in our local population. It is the first out of the United Kingdom to demonstrate data that is consistent with current literature, thus we can suggest that these medications increase the number of False Positives from the FIT (with a FIT cut-off score of >10ugHb/g). From further analysis we will look to answer to the question. ‘Whether having anti-thrombotic medication can increase the likelihood of smaller cancers bleeding?'